Please use this identifier to cite or link to this item:
https://hdl.handle.net/2440/93411
Citations | ||
Scopus | Web of Science® | Altmetric |
---|---|---|
?
|
?
|
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Olver, I. | - |
dc.contributor.author | Grimison, P. | - |
dc.contributor.author | Chatfield, M. | - |
dc.contributor.author | Stockler, M. | - |
dc.contributor.author | Toner, G. | - |
dc.contributor.author | Gebski, V. | - |
dc.contributor.author | Harrup, R. | - |
dc.contributor.author | Underhill, C. | - |
dc.contributor.author | Kichenadasse, G. | - |
dc.contributor.author | Singhal, N. | - |
dc.contributor.author | Davis, I. | - |
dc.contributor.author | Boland, A. | - |
dc.contributor.author | McDonald, A. | - |
dc.contributor.author | Thomson, D. | - |
dc.date.issued | 2013 | - |
dc.identifier.citation | Supportive Care in Cancer, 2013; 21(6):1561-1568 | - |
dc.identifier.issn | 0941-4355 | - |
dc.identifier.issn | 1433-7339 | - |
dc.identifier.uri | http://hdl.handle.net/2440/93411 | - |
dc.description.abstract | PURPOSE: The purpose of this study was to determine the efficacy of adding a 7-day aprepitant schedule to a 5HT3 receptor antagonist and dexamethasone for patients with germ cell tumors receiving first-line 5-day cisplatin-based chemotherapy. METHODS: In a single-arm, open-label, multi-center, phase 2 trial, chemo-naive patients received aprepitant 125 mg PO (per oral) on day 1 and 80 mg PO on days 2 to 7, a 5HT3 receptor antagonist on days 1 to 5, and dexamethasone 8 mg on days 1 to 8. The primary endpoint was no emesis (vomiting or dry retching) during days 1 to 7 of cycle 1. RESULTS: Fifty patients were recruited. For cycle 1, proportions reporting no emesis on day 1, no emesis on days 1 to 7, no nausea on day 1, and no nausea on days 1 to 7 were 96, 82, 71, and 27%, respectively. The efficacy was maintained in all cycles with over 80% of patients reporting no emesis on any given day of any given cycle. Emesis was more common on days 4 to 7 (68% episodes) than on days 1 to 3 (32% episodes). Over any 24-h period, 49% of patients with emesis reported no more than two episodes, and 62% of patients with nausea reported intensity as 3 or less on a scale from 0 to 10. There were no unexpected or serious adverse events reported. CONCLUSION: Adding 7 days of aprepitant to a 5HT3 receptor antagonist and dexamethasone effectively controlled acute and delayed emesis with 5-day cisplatin regimens. Days of nausea were more common than days of vomiting. | - |
dc.description.statementofresponsibility | I. N. Olver, P. Grimison, M. Chatfield, M. R. Stockler, G. C. Toner, V. Gebski, R. Harrup, C. Underhill, G. Kichenadasse, N. Singhal, I. D. Davis, A. Boland, A. McDonald, D. Thomson, for the Australian and New Zealand Urogenital and Prostate Cancer Trials Group | - |
dc.language.iso | en | - |
dc.publisher | Springer Verlag | - |
dc.rights | © Springer-Verlag Berlin Heidelberg 2012 | - |
dc.source.uri | http://dx.doi.org/10.1007/s00520-012-1696-0 | - |
dc.subject | Aprepitant | - |
dc.subject | Dexamethasone | - |
dc.subject | 5Hydroxytryptamine3 receptor antagonist | - |
dc.subject | 5-day cisplatin | - |
dc.subject | Antiemetic | - |
dc.subject | Germ cell tumors | - |
dc.title | Results of a 7-day aprepitant schedule for the prevention of nausea and vomiting in 5-day cisplatin-based germ cell tumor chemotherapy | - |
dc.type | Journal article | - |
dc.identifier.doi | 10.1007/s00520-012-1696-0 | - |
dc.relation.grant | NHMRC | - |
pubs.publication-status | Published | - |
dc.identifier.orcid | Olver, I. [0000-0001-5478-1576] | - |
Appears in Collections: | Aurora harvest 7 Medicine publications |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.